Fabiana Rossi

Dr. Fabiana Rossi

IIMT-CONICET-Austral University
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2021 in Oncogenesis
Verified
Journal Article
Open access
PDF file
Fabiana RossiFabiana Rossi
Fabiana Rossi
JSJuliana Haydeé Enriqué Steinberg
Juliana Haydeé Enriqué Steinberg
EREzequiel Calvo Roitberg
Ezequiel Calvo Roitberg
MJMolishree Umesh Joshi
Molishree Umesh Joshi
APAhwan Pandey
Ahwan Pandey
MRMario Rossi
Mario Rossi
Tumor cell dissemination in cancer patients is associated with a significant reduction in their survival and quality of life. The ubiquitination pathway plays a fundamental role in the maintenance of protein homeostasis both in normal and stressed conditions and its dysregulation has been associated with malignant transformation and invasive potential of tumor cells, thus highlighting its value as a potential therapeutic target. In order to identify novel molecular targets of tumor cell migration and invasion we performed a genetic screen with an shRNA library against ubiquitination pathway-related genes. To this end, we set up a protocol to specifically enrich positive migration regulator candidates. We identified the deubiquitinase USP19 and demonstrated that its silencing reduces the migratory and invasive potential of highly invasive breast cancer cell lines. We extended our investigation in vivo and confirmed that mice injected with USP19 depleted cells display increased tumor-free survival, as well as a delay in the onset of the tumor formation and a significant reduction in the appearance of metastatic foci, indicating that tumor cell invasion and dissemination is impaired. In contrast, overexpression of USP19 increased cell invasiveness both in vitro and in vivo, further validating our findings. More importantly, we demonstrated that USP19 catalytic activity is important for the control of tumor cell migration and invasion, and that its molecular mechanism of action involves LRP6, a Wnt co-receptor. Finally, we showed that USP19 overexpression is a surrogate prognostic marker of distant relapse in patients with early breast cancer. Altogether, these findings demonstrate that USP19 might represent a novel therapeutic target in breast cancer.

15 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Fabiana RossiFabiana Rossi
Fabiana Rossi
EREzequiel Calvo Roitberg
Ezequiel Calvo Roitberg
JSJuliana Haydeé Enriqué Steinberg
Juliana Haydeé Enriqué Steinberg
MJMolishree Joshi
Molishree Joshi
JEJoaquín Maximiliano Espinosa
Joaquín Maximiliano Espinosa
MRMario Rossi
Mario Rossi
Tumor cell migration and invasion into adjacent tissues is one of the hallmarks of cancer and the first step towards secondary tumors formation, which represents the leading cause of cancer-related deaths. This process is considered an unmet clinical need in the treatment of this disease, particularly in breast cancers characterized by high aggressiveness and metastatic potential. To identify and characterize genes with novel functions as regulators of tumor cell migration and invasion, we performed a genetic loss-of-function screen using a shRNA library directed against the Ubiquitin Proteasome System (UPS) in a highly invasive breast cancer derived cell line. Among the candidates, we validated HERC1 as a gene regulating cell migration and invasion. Furthermore, using animal models, our results indicate that HERC1 silencing affects primary tumor growth and lung colonization. Finally, we conducted an in silico analysis using publicly available protein expression data and observed an inverse correlation between HERC1 expression levels and breast cancer patients’ overall survival. Altogether, our findings demonstrate that HERC1 might represent a novel therapeutic target for the development or improvement of breast cancer treatment.

8 April 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
DJDiego M. Jofré
Diego M. Jofré
DHDane K. Hoffman
Dane K. Hoffman
ACAilen S. Cervino
Ailen S. Cervino
GHGabriella M. Hahn
Gabriella M. Hahn
MGMcKenzie Grundy
McKenzie Grundy
DHDaniel Hochbaum
Daniel Hochbaum
Significance: CHARGE syndrome is a complex developmental disorder caused by mutations in CHD7 (chromodomain helicase DNA-binding protein-7). We identified Caenorhabditis elegans chd-7 in a screen for suppressors of dauer formation, an alternative larval stage that develops under harsh environmental conditions. We found chd-7 regulates tumor growth factor-β (TGF-β) signaling pathways both for dauer diapause and for development of the cuticle, a specialized extracellular matrix. In frog embryos, Chd7 promotes Col2a1 expression, which is necessary and sufficient to prevent CHARGE features. These studies establish a conserved role for Chd7 from worms to vertebrates in regulating the TGF-β signaling pathway. Genetic dissection of chd-7 ’s role in C. elegans may help to define the molecular and cellular events that contribute to CHARGE syndrome.

26 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
DJDiego Martín Jofré
Diego Martín Jofré
DHDane Kristian Hoffman
Dane Kristian Hoffman
ACAilen S. Cervino
Ailen S. Cervino
MGMcKenzie Grundy
McKenzie Grundy
SYSijung Yun
Sijung Yun
DHDaniel Hochbaum
Daniel Hochbaum
CHARGE syndrome is a complex developmental disorder caused by mutations in the chromodomain helicase DNA-binding protein7 (CHD7) and characterized by retarded growth and malformations in the heart and nervous system. Despite the public health relevance of this disorder, relevant targets of CHD7 that relate to disease pathology are still poorly understood. Here we report that chd-7 , the nematode ortholog of Chd7, is required for dauer morphogenesis, lifespan determination, and stress response. Consistent with our discoveries, we found chd-7 to be allelic to scd-3 , a previously identified dauer suppressor from the TGF-β pathway. Notably, DAF-12 promoted chd- 7 expression, which is necessary to repress daf-9 for execution of the dauer program. Transcriptomic analysis comparing chd-7– defective and normal dauers showed enrichment of collagen genes, consistent with a conserved role for the TGF-β pathway in formation of the extracellular matrix. To validate a conserved function for chd-7 in vertebrates, we used Xenopus laevis embryos, an established model to study craniofacial development. Morpholino mediated knockdown of Chd7 led to a reduction in col2a1 mRNA levels. Both embryonic lethality and craniofacial defects in Chd7-depleted tadpoles were partially rescued by over-expression of col2a1 mRNA. We suggest that pathogenic features of CHARGE syndrome caused by Chd7 mutations, such as craniofacial malformations, result from the reduction of collagen levels, implying that the extracellular matrix might represent a critical target of Chd7 in CHARGE development. SIGNIFICANCE STATEMENT: CHARGE Syndrome is a complex developmental disorder caused by mutations in the chromodomain helicase DNA-binding protein-7 (CHD7). Unfortunately, the cellular events that lead to CHARGE syndrome are still poorly understood. In C. elegans , we identified chd-7 in a screen for suppressors of dauer formation, an alternative larval stage that develops in response to sensory signals of a harsh environment. We found that chd-7 regulates expression of collagens, which constitute the worm’s cuticle, a specialized extracellular matrix. In frog’s embryos, we show that Chd7 inhibition leads to poor Col2a1, which is necessary and sufficient to exhibit CHARGE features. These studies establish C. elegans as an amenable animal model to study the etiology of the developmental defects associated with pathogenic Chd7.

5 November 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
Fabiana RossiFabiana Rossi
Fabiana Rossi
EREzequiel Hernán Calvo Roitberg
Ezequiel Hernán Calvo Roitberg
JSJuliana Haydeé Enriqué Steinberg
Juliana Haydeé Enriqué Steinberg
MJMolishree Joshi
Molishree Joshi
JEJoaquín Maximiliano Espinosa
Joaquín Maximiliano Espinosa
MRMario Rossi
Mario Rossi
Tumor cell migration and invasion into adjacent tissues is one of the hallmarks of cancer and the first step towards secondary tumors formation, which represents the leading cause of cancer-related deaths. This process is considered an unmet clinical need in the treatment of this disease, particularly in breast cancers characterized by high aggressiveness and metastatic potential. In order to identify and characterize genes with novel functions as regulators of tumor cell migration and invasion, we performed a genetic loss-of-function screen using a shRNA library directed against the Ubiquitin Proteasome System (UPS) in a highly invasive breast cancer derived cell line. Among the candidates, we validated HERC1 as a gene regulating cell migration and invasion. Furthermore, using animal models, our results indicated that HERC1 silencing affects primary tumor growth and lung colonization. Finally, we conducted an in-silico analysis using publicly available protein expression data and observed an inverse correlation between HERC1 expression levels and breast cancer patients’ overall survival. Altogether, our findings demonstrate that HERC1 might represent a novel therapeutic target for the development or improvement of breast cancer treatment.

3 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
Fabiana RossiFabiana Rossi
Fabiana Rossi
JSJuliana H Enriqué Steinberg
Juliana H Enriqué Steinberg
EREzequiel H Calvo Roitberg
Ezequiel H Calvo Roitberg
MJMolishree Joshi
Molishree Joshi
APAhwan Pandey
Ahwan Pandey
MRMario Rossi
Mario Rossi
Tumor cell dissemination in cancer patients is associated with a significant reduction in their survival and quality of life. The ubiquitination pathway plays a fundamental role in the maintenance of protein homeostasis both in normal and stressed conditions and its dysregulation has been associated with malignant transformation and invasive potential of tumor cells, thus highlighting its value as a potential therapeutic target. In order to identify novel molecular targets of tumor cell migration and invasion we performed a genetic screen with an shRNA library against ubiquitination pathway-related genes. To this end, we set up a protocol to specifically enrich positive migration regulator candidates. We identified the deubiquitinase USP19 and demonstrated that its silencing reduces the migratory and invasive potential of highly invasive breast cancer cell lines. We extended our investigation in vivo and confirmed that mice injected with USP19 depleted cells display increased tumor-free survival, as well as a delay in the onset of the tumor formation and a significant reduction in the appearance of metastatic foci, indicating that tumor cell invasion and dissemination is impaired. In contrast, overexpression of USP19 increased cell invasiveness both in vitro and in vivo , further validating our findings. More importantly, we demonstrated that USP19 catalytic activity is important for the control of tumor cell migration and invasion, and that its molecular mechanism of action involves LRP6, a Wnt co-receptor. Finally, we showed that USP19 overexpression is a surrogate prognostic marker of distant relapse in patients with early breast cancer. Altogether, these findings demonstrate that USP19 might represent a novel therapeutic target in breast cancer.